PGI2

Test Ligands Values Explained

Test Ligand ID - A unique identifier for the test ligand
Ligand Name - Name of the test ligand

Test Ligand ID5296
Ligand NamePGI2
PubMed Compound Id5282411
StructureProduct Image
Molecular FormulaC20H32O5
Molecular Weight352.5
SMILESCCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O
Synonymsepoprostenol
prostaglandin I2
PGI2
Vasocyclin
Prostaglandin X
Epoprostenolum
Prostacyclin I2
PGI(sub 2)
KB-IV-24
VentaProst
Epoprostenolum [INN-Latin]
PGX
UNII-DCR9Z582X0
DCR9Z582X0
CHEBI:15552
U-53217
BRN 1690090
U-53,217
DTXSID5022988
U 53217
6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
Epoprostanol
(5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
Epoprostenolum (INN-Latin)
Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9alpha,11alpha,13E,15S)-
EPOPROSTENOL (MART.)
EPOPROSTENOL [MART.]
Prostaglandin I(2)
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
epoprostenolo
(5z,13e)-(15s)-6,9-alpha-epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoate
DTXCID602988
B01AC09
(Z)-(3AR,4R,5R,6AS)-HEXAHYDRO-5-HYDROXY-4-((E)-(3S)-3-HYDROXY-1-OCTENYL)-2H-CYCLOPENTA(B)FURAN-delta(SUP 2,delta)-VALERATE
prostacyclin
35121-78-9
ACT-385781A
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(3Ar,4R,5R,6aR)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(Z)-5-((3aR,4R,5R,6aS)-5-hydroxy-4-((S,E)-3-hydroxyoct-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-ylidene)pentanoic acid
6,9S-epoxy-11R,15S-dihydoxy-5Z,13E-prostadienoic acid
Epoprostenol [USAN:INN]
Prosta-5,13-dien-1-oicacid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9a,11a,13E,15S)-
PG-I2
U 53,217
PROSTACYCLIN [MI]
EPOPROSTENOL [INN]
EPOPROSTENOL [USAN]
SCHEMBL8041
CHEMBL1139
EPOPROSTENOL [VANDF]
BSPBio_001496
(Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid
BIDD:GT0514
EPOPROSTENOL [WHO-DD]
GTPL1915
HMS1791K18
HMS1989K18
HMS3402K18
HY-A0126
LMFA03010087
AKOS040744695
DB01240
(5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid
IDI1_033966
SMP2_000227
NCGC00161285-01
NCGC00161285-02
NCGC00161285-03
CS-0017443
NS00007986
EN300-21690431
Q412050
BRD-K64054020-001-02-7
BRD-K64054020-001-03-5
6,9.alpha.-Epoxy-11.alpha.,15S-dihydroxyprosta-5Z,13E-dien-1-oic acid, monosodium salt
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[d]furan-2-ylidene]pentanoic acid
(Z)-(3AR,4R,5R,6AS)-HEXAHYDRO-5-HYDROXY-4-((E)-(3S)-3-HYDROXY-1-OCTENYL)-2H-CYCLOPENTA(B)FURAN-.DELTA.(SUP 2,.DELTA.)-VALERATE
5-[(2Z,3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-hexahydro-2H-cyclopenta[b]furan-2-ylidene]pentanoic acid
PROSTA-5,13-DIEN-1-OIC ACID, 6,9-EPOXY-11,15-DIHYDROXY-, (5Z,9.ALPHA.,11.ALPHA.,13E,15S)-
Created AtJan 13, 2025 2:47 pm
Updated AtJan 13, 2025 2:47 pm